mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

被引:335
作者
Guertin, David A. [1 ,2 ,3 ]
Stevens, Deanna M. [1 ]
Saitoh, Maki [1 ,2 ]
Kinkel, Stephanie [1 ,2 ,3 ]
Crosby, Katherine [4 ]
Sheen, Joon-Ho [1 ,2 ,3 ]
Mullholland, David J. [5 ]
Magnuson, Mark A. [6 ,7 ]
Wu, Hong [5 ]
Sabatini, David M. [1 ,2 ,3 ,8 ]
机构
[1] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[2] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA
[3] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
[4] Cell Signaling Technol, Danvers, MA 01923 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[6] Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA
[7] Vanderbilt Univ, Ctr Stem Cell Biol, Sch Med, Nashville, TN 37232 USA
[8] MIT & Harvard, Broad Inst, Cambridge, MA 02141 USA
基金
美国国家卫生研究院;
关键词
RICH AKT-SUBSTRATE; MOTIF PHOSPHORYLATION; TUMOR-DEVELOPMENT; SUPPRESSOR GENE; TOR COMPLEX-2; KINASE-B; RICTOR; RAPAMYCIN; ACTIVATION; AKT/PKB;
D O I
10.1016/j.ccr.2008.12.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
mTOR complex 2 (mTORC2) contains the mammalian target of rapamycin (mTOR) kinase and the Rictor regulatory protein and phosphorylates Akt. Whether this function of mTORC2 is critical for cancer progression is unknown. Here, we show that transformed human prostate epithelial cells lacking PTEN require mTORC2 to form tumors when injected into nude mice. Furthermore, we find that Rictor is a haploinsufficient gene and that deleting one copy protects Pten heterozygous mice from prostate cancer. Finally, we show that the development of prostate cancer caused by Pten deletion specifically in prostate epithelium requires mTORC2, but that for normal prostate epithelial cells, mTORC2 activity is nonessential. The selective requirement for mTORC2 in tumor development suggests that mTORC2 inhibitors may be of substantial clinical utility.
引用
收藏
页码:148 / 159
页数:12
相关论文
共 56 条
  • [11] In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation
    Collins, BJ
    Deak, M
    Arthur, JSC
    Armit, LJ
    Alessi, DR
    [J]. EMBO JOURNAL, 2003, 22 (16) : 4202 - 4211
  • [12] PTEN, a unique tumor suppressor gene
    Dahia, PLM
    [J]. ENDOCRINE-RELATED CANCER, 2000, 7 (02) : 115 - 129
  • [13] Pten is essential for embryonic development and tumour suppression
    Di Cristofano, A
    Pesce, B
    Cordon-Cardo, C
    Pandolfi, PP
    [J]. NATURE GENETICS, 1998, 19 (04) : 348 - 355
  • [14] The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C
    Facchinetti, Valeria
    Ouyang, Weiming
    Wei, Hua
    Soto, Nelyn
    Lazorchak, Adam
    Gould, Christine
    Lowry, Carolyn
    Newton, Alexandra C.
    Mao, Yuxin
    Miao, Robert Q.
    Sessa, William C.
    Qin, Jun
    Zhang, Pumin
    Su, Bing
    Jacinto, Estela
    [J]. EMBO JOURNAL, 2008, 27 (14) : 1932 - 1943
  • [15] Genetic background controls tumor development in Pten-deficient mice
    Freeman, Dan
    Lesche, Ralf
    Kertesz, Nathalie
    Wang, Shungyou
    Li, Gang
    Gao, Jing
    Groszer, Matthias
    Martinez-Diaz, Hilda
    Rozengurt, Nora
    Thomas, George
    Liu, Xin
    Wu, Hong
    [J]. CANCER RESEARCH, 2006, 66 (13) : 6492 - 6496
  • [16] mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s
    Frias, Maria A.
    Thoreen, Carson C.
    Jaffe, Jacob D.
    Schroder, Wayne
    Sculley, Tom
    Carr, Steven A.
    Sabatini, David M.
    [J]. CURRENT BIOLOGY, 2006, 16 (18) : 1865 - 1870
  • [17] mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
    Garcia-Martinez, Juan M.
    Alessi, Dario R.
    [J]. BIOCHEMICAL JOURNAL, 2008, 416 : 375 - 385
  • [18] Defining the role of mTOR in cancer
    Guertin, David A.
    Sabatini, David M.
    [J]. CANCER CELL, 2007, 12 (01) : 9 - 22
  • [19] Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα but not S6K1
    Guertin, David A.
    Stevens, Deanna M.
    Thoreen, Carson C.
    Burds, Aurora A.
    Kalaany, Nada Y.
    Moffat, Jason
    Brown, Michael
    Fitzgerald, Kevin J.
    Sabatini, David M.
    [J]. DEVELOPMENTAL CELL, 2006, 11 (06) : 859 - 871
  • [20] Structure, regulation and function of PKB/AKT - a major therapeutic target
    Hanada, M
    Feng, JH
    Hemmings, BA
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2004, 1697 (1-2): : 3 - 16